Explore Toxoplasma, a common parasite affecting one-third of the population. Discover how new imaging techniques aid research ...

It infects nearly one-third of the global population, yet its microscopic size makes the Toxoplasma gondii parasite difficult ...

Pharmacosmos initiates phase III clinical trial of trilaciclib in limited-stage small cell lung cancer MORRISTOWN, NJ, ...

A simulated cell in the early stages of division. Left half shows membrane (green cubes), and ribosomes (yellow/purple) ...

Inherited blood disorders remain one of the most persistent yet under-recognised public health challenges in India. Among ...

Highlighting Positive Results in Comparison to Valchlor(R) and in Real-World Use PRINCETON, N.J., March 23, 2026 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage ...

Gilead Sciences is paying $1.67 billion for a T-cell engager (TCE) company via a front-loaded deal that could also give new meaning to its partner Galapagos. By acquiring GSK-founded Ouro Medicines, ...

Pfizer Inc. (NYSE: PFE) today announced positive topline results from the randomized Phase 2 FOURLIGHT-1 study evaluating ...

Ractigen Therapeutics, a pioneering clinical-stage biotechnology company developing innovative small activating RNA (saRNA) therapeutics, today announced that China's National Medical Products ...

Mosaic Therapeutics, Ltd, (‘Mosaic’, or ‘the Company’) a clinical-stage oncology therapeutics company building the category leader in Synergistic Precision Oncology, today announced it will hold a ...

Gilead Sciences, Inc. (Nasdaq: GILD) announced today it has entered into a definitive agreement to acquire Ouro Medicines, a ...

(Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, ...